Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study - The Lancet Oncology

Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review)

Precision treatment for metastatic non–small cell lung cancer: A conceptual overview

Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor–activating mutation-positive non–small-cell lung cancer patients in Hong Kong

Cancers, Free Full-Text

Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor–activating mutation-positive non–small-cell lung cancer patients in Hong Kong

Treatment of Stage III B - IV Non-Small Cell Lung Cancer - CancerConnect

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study - ScienceDirect

Current and Future Therapeutics for Patients with Non-small Cell Lung Cancer and Known Activating Mutations in Epidermal Growth Factor Receptor - touchONCOLOGY

Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer - touchONCOLOGY

Cells, Free Full-Text